Nutlins were the first potent and selective inhibitors of the MDM2-p53 interaction (Vassilev et al., 2004), in particular Nutlin-3 has been extensively evaluated in vitro and in vivo in several types of human cancers and the cis-imidazoline RG7112 is currently in phase I clinical trials3 (NCT00559533 and NCT00623870). The gene discussed is TP53; the disease is cancer.